Alzheimer therapy from Jülich passes another important test

The Alzheimer drug candidate PRI-002 developed at Forschungszentrum Jülich has successfully completed Phase I of clinical research involving healthy volunteers. When administered daily over a period of four weeks, the active substance proved to be safe for use in humans. The next milestone will be the proof of efficacy in patients in clinical Phase II.

Quelle: IDW Informationsdienst Wissenschaft